Certain aspects of the disclosure provide systems and methods for generating predictions of mood disorder. For example, one method may include presenting a set of stimuli and receiving a set of ratings for the set of stimuli from a subject. The method further includes determining a set of judgment variables based on the set of ratings. The method further incudes generating a mood disorder prediction based on the set of judgment variables and treating the subject based on the mood disorder prediction.
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
G16H 40/00 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
Provided herein is technology relating to anticoagulant therapies and particularly, but not exclusively, to anticoagulant compositions for localized and targeted administration and related methods and kits for treatment of a subject with a localized and targeted anticoagulant therapy.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Disclosed are methods for expanding T regulatory cells (Tregs) that are antigen specific, populations of Tregs, pharmaceutical compositions comprising the populations of Tregs. Also disclosed are methods of using the antigen specific Tregs, e.g., alloantigen specific Tregs for the treatment of tissue rejection, autoimmune, allergic, and other diseases or disorders characterized by a pathological immune response.
The present disclosure provides tri-specific T cell engagers that bind to IL13Ra2, EGFRvIII, and CD3. The disclosure further provides methods of using the tri-specific T cell engagers to treat a cancer, such as glioblastoma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
6.
POLYMERIC NANOCARRIERS FOR DELAYING ONSET OF TYPE I DIABETES
Disclosed herein are methods for delaying the onset of type I diabetes and preventing nosocomial infections by administering PEG-b-PPS nanocarriers loaded with rapamycin. This invention aims to reduce the frequency of visits to a transfusion clinic, reduce the costs of treatments, and reduce adverse side effects, without reducing the effects of the islet transplant. This is accomplished by the use of a nanocarrier which targets treatment to the desired location.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present disclosure provides methods of producing and expanding populations of B cells (e.g., human B cells for clinical applications). Such expanded populations can be used to produce B cell vaccines containing B cells that express 4-1BBL and are capable of promoting tumor cell death.
An implantable device for monitoring a physiological status and administering drugs therefor includes at least one drug reservoir for containing at least one drug solution; a delivering member coupled to the at least one drug reservoir for operably delivering the at least one drug solution from the at least one drug reservoir to the living subject; a sensor member for measuring physiological parameters of a living subject so as to monitor a physiological status of the living subject; a wireless communication system for wireless data transmission; a power management system for wireless power harvesting; and a controller coupled to the power management system, the wireless communication system, the sensor member and the delivering member for wireless data transmission and power harvesting; obtaining the physiological status of the living subject, and controlling operations of the delivering member based on the physiological status of the living subject.
United States Government As Represented By The Department Of Veterans (USA)
Northwestem University (USA)
Inventor
Murray, Wendy M.
Perreauit, Eric
Sun, Cheng
Collins, Caralyn
Gillespie, Samuel
Abstract
A phantom has a structure that, when subject to a B-mode ultrasound, is configured to generate return waves that mimic return waves produced by muscle tissue when subjected to B-mode ultrasound. The phantom has a longitudinal axis. The structure includes a first material. The structure defines a plurality of regions free of the first material along a first transverse axis perpendicular to the longitudinal axis.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A system to identify and predict atrial fibrillation includes a memory configured to store one or more electrograms and one or more nerve recordings of a patient. The system also includes a processor operatively coupled to the memory and configured to identify one or more atrial fibrillation characteristics based on the one or more electrograms and the one or more nerve recordings, where the one or more atrial fibrillation characteristics include oxidative stress and fibrosis. The processor is also configured to identify a progression state of the atrial fibrillation based on the one or more atrial fibrillation characteristics.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
Systems and methods described herein include a logical computing framework designed to generate engaging multimodal image-text pairs. For example, this logical computing framework for generating engaging multimodal content (GEM) may be used to create online advertisements that effectively capture users' attention with a blend of images and text. The GEM framework operates in two steps. First, GEM combines a pre-trained engaging discriminator with a method for learning an effective continuous prompt for a stable diffusion model. Next, GEM operates with an iterative algorithm to generate coherent, engaging image-sentence pairs based on a given topic of interest. Results demonstrate that the image-sentence pairs generated by GEM are not only more engaging but also exhibit better alignment compared to several baseline approaches.
G06Q 30/0242 - Determining effectiveness of advertisements
G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
Systems and methods described herein include a logical computing framework (JUST) within which judges can record propositions about a case and witness statements where a witness says that certain propositions are true. The logical computing framework may provide a user interface that allows the judge to assign a probability of her belief in a witness statement. For example, a world is an assignment of true or false to each proposition, which is required to satisfy case specific integrity constraints. The logical computing framework processes an explicit algorithm that calculates the k-most likely worlds without using independence assumptions between propositions. The judge may use these calculated top-k most probable worlds to make his or her final decision. For this computation, the logical computing framework incorporates and uses a suite of “combination” functions. Additionally, the logical computing framework incorporates an implicit and efficient algorithm.
Disclosed are substituted indole compounds and other substituted nitrogen-containing heteroaryl compounds. The disclosed compounds and compositions thereof may be utilized in methods for inhibiting kalirin, including methods for treating and/or preventing diseases or disorders associated with kalirin activity or expression such as neuropathic pain, chronic pain, and epilepsy.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides methods and compositions for sensitizing glioma cells to immunotherapy by contacting the cells with a Sec61 complex inhibitor.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 43/00 - Drugs for specific purposes, not provided for in groups
16.
USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS
Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
An implantable hybrid advanced molecular manufacturing regulator device containing engineered cells delivering cancer therapeutics to a subject. The device comprises a conductive scaffold in communication with a control module; a biochemical sensor module in communication with the control module; an oxygenator configured to produce oxygen and disposed inside the conductive scaffold; and at least one engineered cells encapsulation disposed in association with the conductive scaffold; wherein the at least one engineered cells encapsulation encapsulates engineered cells; wherein the engineered cells are configured to produce at least one cancer therapeutic agent; wherein the device is implantable.
An implantable hybrid advanced molecular manufacturing regulator device comprises a control module, a conductive scaffold in communication with the control module; a biochemical sensor module in communication with the control module; and an oxygenator disposed inside the conductive scaffold.
A biohybrid device housing engineered cells expressing at least one therapeutic agent comprises a conductive scaffold in communication with a control module; an oxygenator disposed inside the conductive scaffold; engineered cells encapsulated in a biomaterial disposed inside the conductive scaffold, wherein each of the engineered cells comprises at least one vector; and wherein the at least one vector has at least one promoter followed by at least one peptide encoding sequence.
A platform of a hybrid advanced molecular manufacturing regulator device containing engineered cells delivering cancer therapeutics to a subject comprises an implantable device disposed inside an internal cavity of a subject; and an external device disposed outside the internal cavity of the subject and in wireless communication with the implantable device, wherein the implantable device comprises a molecular manufacturing regulator and a communication module; wherein the external device comprises at least one transmission coil in wireless communication with the communication module.
In some aspects, provided herein compounds (PROTACs) targeting the E3 ligase FBXO22 and uses thereof. In some aspects, provided herein are methods of identifying E3 ligases and compounds that support targeted protein degradation.
Vertical organic electrochemical transistors (vOECTs), high-density arrays of the vOECTs, and complementary circuits that incorporate the vOECTs are provided. Also provided are methods of making the vOECTs via micropatterning of redox-active organic semiconductor films by direct electron-beam (e-beam) exposure. In the fabrication methods, highly energetic electrons convert exposed areas of an organic semiconductor into an electronic insulator that retains ionic conductivity, while unexposed areas of the organic semiconductor remain redox-active. This vOECT fabrication approach results in topological continuity between the electrically insulating areas and the redox-active areas of the organic film, which facilitates monolithic integration.
H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]
H10K 19/00 - Integrated devices, or assemblies of multiple devices, comprising at least one organic element specially adapted for rectifying, amplifying, oscillating or switching, covered by group
H10K 19/10 - Integrated devices, or assemblies of multiple devices, comprising at least one organic element specially adapted for rectifying, amplifying, oscillating or switching, covered by group comprising field-effect transistors
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.
C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Disclosed herein is a method for proteoform-specific antigen identification. The method may comprise infusing a sample comprising an antigen and an antigen-binding protein into a mass spectrometer; isolating a complex comprising the antigen bound to the antigen-binding protein; ejecting the bound antigen from the complex; and identifying the ejected antigen and/or identifying the antigen-binding protein.
Methods and compositions for making organic crosslinkers having hindered urea bonds and methods and compositions for making dynamic crosslinked polymer networks using the organic crosslinkers via addition chemistry are provided. Also provided are methods for processing and reprocessing the dynamic crosslinked polymer networks in which the crosslinkers dissociate at elevated temperatures and recombine upon cooling. Polymer networks formed using the dynamic crosslinkers can be reprocessed multiple times at modest temperatures with full recovery of crosslink density.
Described herein are methods, compositions, and cyclophanes for live cell imaging. The method comprises irradiating a cell in contact with a composition for live cell imaging and detecting an emission signal, wherein the composition for live cell imaging comprises a cyclophane having an alternating cyclic arrangement of two A subunits and two B subunits.
in vivoin vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NFAT, NF-κB and/or AP-1 pathways. The disclosure also provides vectors and cells including the recombinant nucleic acid constructs of the disclosure as well as methods of using the receptors.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
29.
BIOSYNTHESIS OF HIERARCHICAL METAL ORGANIC FRAMEWORK-BACTERIAL CELLULOSE COMPOSITES
Composites of metal-organic framework particles and bacterial cellulose, methods of making the composites, and methods of using the composites in the hydrolysis of organic compounds are provided. The composites, which are aerogels comprising metal-organic framework particles embedded in a bacterial cellulose nanofiber network, are fabricated using a microbial synthesis strategy in which bacterial cellulose nanofiber is biosynthesized using a cellulose-producing bacteria in a fermentation medium in which metal-organic framework particles are dispersed.
The present disclosure is directed to spherical nucleic acids (SNAs) comprising a nanoparticle core and an oligonucleotide shell attached to the external surface of the nanoparticle core, wherein the oligonucleotide shell comprises a mixture of class A CpG oligonucleotides and class B CpG oligonucleotides. The disclosure also provides methods of using the SNAs for, e.g., regulation of an immune response and gene regulation.
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A method of Convolution-Hierarchical Deep-learning Neural Network isogeometric Analysis (C-IGA) of a geometric shape of a subject matter comprises performing a first mapping process between a physical domain of a subject matter and a parametric domain of the subject matter; and performing a second mapping process between the parametric domain of the subject matter and a parent domain of the subject matter; wherein the first mapping process comprises constructing an C-IGA interpolation in the parametric domain based on CAD data of the subject matter.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
A mechanistic nested topological design optimization method for using Convolution-Hierarchical Deep-learning Neural Network Tensor Decomposition (C-HiDeNN-TD) comprises (1) obtaining at least one design variable and at least one design requirement; (2) decomposing the at least one design variable into at least one equation in each of at least two directions; (3) solving the at least one design variable in each of the at least two directions using a C-HiDeNN-TD solver to obtain at least one part design; and (4) outputting an optimal design based on the at least one part design when the optimal design meets the least one design requirement.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
G06F 30/17 - Mechanical parametric or variational design
The invention provides an implantable device and method of monitoring wirelessly and continuously thermal conductivity and blood flow on the surface of a target region of a subject. The implantable device comprises a probe operably attached to the target region; and an electronic module coupled with the probe for wireless, real-time, and continuous measurements of physiological information of the target region.
Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of central nervous system disorders.
The present disclosure relates, in general, to synthetic, spherical lipoprotein-like nanoparticles comprising an organic core material that provides properties that are similar to mature human HDLs and use thereof to treat disorders such as cancer or immune disorders. In various embodiments, the disclosure provides a spherical lipoprotein-like nanoparticle (HDL-NP) comprising: a core and a shell surrounding and attached to the core, wherein the core comprises a lipid conjugated organic scaffold comprising a dendritic lipid scaffold.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Organic electrochemical transistors (OECTs) that include a conducting channel composed of a bilayer of a p-type organic mixed ionic and electronic conductor adjacent to an n-type organic mixed ionic and electronic conductor are provided. The bilayer channel of the OECTs exhibits anti-ambipolar (OFF-ON-OFF) switching upon the application of a gate voltage, whereby a current flows through the channel when both layers of the bilayer are in an “ON” (conducting) state, but not when either or both layers are in an “OFF” (non-conducting) state.
H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]
H10K 19/10 - Integrated devices, or assemblies of multiple devices, comprising at least one organic element specially adapted for rectifying, amplifying, oscillating or switching, covered by group comprising field-effect transistors
Disclosed are components, systems, methods, and kits for synthesis of diamerized, clickable antigen binding fragments, such as Fab fragments, and uses thereof. The components, systems, methods, and kits disclosed herein utilize cell-free protein synthesis (CFPS) systems and methods to produce clickable antigen binding fragments.
The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the linker includes a first and second functional groups specific for irreversibly inhibiting the first and second fusion protein reactive enzymes. The disclosure further provides a method including (a) contacting a first fusion protein including an affinity reagent and a reactive enzyme with a linker including a functional group specific for irreversibly inhibiting the first fusion protein reactive enzyme thereby coupling the first fusion protein and the linker, and (b) contacting a second fusion protein including an affinity reagent and a reactive enzyme with the linker, the linker including a functional group specific for irreversibly inhibiting the second fusion protein reactive enzyme thereby coupling the second fusion protein and the linker.
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A smart face mask device includes a housing that is designed to mount to a personal protective face mask and a memory within the housing that is configured to store sensor data. The device includes one or more sensors configured to generate the sensor data during use of the personal protective mask. The device also includes a processor operatively coupled to the memory and configured to process the sensor data to determine information regarding a user of the personal protective mask, and to transmit the information regarding the user to a remote application.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A41D 13/11 - Protective face masks, e.g. for surgical use, or for use in foul atmospheres
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
40.
METHOD TO EVALUATE AND FACT-CHECK AN AI LARGE LANGUAGE MODEL CHAT RESPONSE USING DOMAIN- SPECIFIC AND DOMAIN-AGNOSTIC GUIDANCE FOR PERSONALIZED MEDICAL PROVIDER-PATIENT CONSULT
A method for evaluating an artificial intelligence (AI) large language model (LLM) generated response, the method comprising receiving a user query in the form of patient-related questions for a medical treatment domain; analyzing the user query using a LLM learned with open-source data and outputting a LLM answer from the LLM; performing a domain-specific evaluation of the LLM answer; performing a domain-agnostic evaluation of the LLM answer; generating at least one metric for the LLM answer based on the domain-specific evaluation and the domain-agnostic evaluation of the LLM answer; and evaluating the quality of the LLM answer based on the at least one metric.
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
41.
GENOME-WIDE CLASSIFIERS FOR DETECTION OF SUBACUTE TRANSPLANT REJECTION AND OTHER TRANSPLANT CONDITIONS
This disclosure provides methods of detecting sub-acute rejection and other categories of rejection in kidney transplant recipients using unique sets of gene expression markers.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
A novel culture media formula that is thoroughly optimized to support high growth rate under low seeding density conditions, require minimal media exchanges, and at low cost, while maintaining differentiation reproducibility is provided. This formula is capable of supporting both human induced pluripotent stem cell (hiPSC) generation and culture for >100 passages. Generation of B8 supplement aliquots suitable for making 100 liters of media is simple for any research lab with basic equipment, with complete bottles of media costing ˜$12 USD per liter. Weekend free hiPSC cell culture methods are possible with this formulation.
A signal multiplication device includes a signal source that generates a bias voltage and a signal source that generates an optical signal. The device also includes an electron injection photodetector that receives the bias voltage and the optical signal. The electron injection photodetector multiplies the bias voltage and the optical signal to generate an output photocurrent that is dependent on the bias voltage.
Disclosed herein are 4-phenoxypyrimidine compounds and derivatives thereof for use as inhibitors of mitogen-activated protein kinase 7 (MEK7). The disclosed compounds and pharmaceutical compositions thereof may be used in methods for treating a disease or disorder associated with MEK7 activity, including cell proliferative diseases and disorders associated with MEK7 activity, such as cancer.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
46.
FUNCTIONALIZED CYCLODEXTRIN MONOMER AND POLYMER FOR WATER REMEDIATION
Disclosed herein are mesoporous polymeric materials and methods for preparing and using the same. The mesoporous polymeric material comprises a network of cyclodextrin moieties crosslinked by a plurality of crosslinks.
The present disclosure is directed to multicomponent assemblies (e.g., crystalline structures) using oligonucleotide dendrimers and spherical nucleic acids (SNAs). The disclosure also provides methods of forming the multicomponent assemblies.
The present disclosure relates to stable, cost-effective, cell-free systems, compositions, methods, and kits for bio-manufacturing proteins. The systems, methods, and kits allow for cell-free bio-manufacturing of desired products in cell-free conditions, wherein the system can be stably stored or transported, in lyophilized form, at temperatures up to 50° C. for several weeks prior to use.
This invention relates to a screen printable electrolyte ink and a device including a microsupercapacitor that is fully printed with the ink. The ink comprises an ionic liquid; and a solid matrix material mixed with the ionic liquid in at least one solvent.
A system and method for predicting cardiovascular function is presented. The method includes accessing physiological measurement data and patient data from a patient. The method also includes accessing a neural network trained to predict cardiovascular function data using the physiological measurement data and patient data.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
51.
DEVICE AND METHOD FOR ASSESSMENT OF SECRETED PROTEINS FROM SINGLE CELLS IN A CULTURE
Provided herein are methods for the high throughput screening of cells secreting a target protein comprising, consisting of, or consisting essentially of obtaining cells for screening, labelling at least one cell surface marker of the cells with a first label that binds to the cell surface marker and a second label specific for the target protein, wherein the second label binds the first label, allowing the cells to secrete the target protein, wherein the secreted target protein attaches to the second label, conjugating the secreted target protein bound to the second label with a magnetic nanoparticle-bound label, and sorting the labeled cells in a microfluidic device based on the target protein secretion levels on the cell surface of the cells, wherein the microfluidic device detects the magnetic nanoparticle-bound label.
Provided herein are engineered bacterial biosensors and methods of use thereof for detection of gastrointestinal disease, including inflammatory bowel disease.
Synthetic methods for forming a crosslinked polymer network with dynamic bonds within its crosslinks from a pre-existing unsaturated organic polymer are provided. The dynamic bonds enable the resulting crosslinked polymer network to be chemically or mechanically recycled or otherwise reprocessed. Also provided are crosslinked polymer networks made using the synthetic methods and methods for reprocessing the crosslinked polymer networks using thiol exchange reactions.
C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
A device for reversibly blocking activities of a target region of a subject includes a microfluidic system configured to route a fluid around the target region to change a local temperature of the target region; and an electronic system coupled with the microfluidic system for providing a real-time feedback.
An optical coherence tomography imaging system is disclosed, including: a light source to generate a radiation beam; a pair of photodetectors to acquire data of the radiation beam; a coupler to direct portions of the beam to a sample arm and a reference arm, the coupler to combine light from the sample arm and the reference arm, the combined light to be split into portions to be detected by the pair of photodetectors; and a processor to measure and compare noise profiles of the data and to generate an image using the data, and the noise profile comparison.
This invention relates to an aortic valve with an embedded pacing device, a method for making the same, and application thereof. The aortic valve includes a valve frame, and a pacing device is disposed and embedded in the valve frame. The pacing device is used to deliver rapid pacing during deployment of the aortic valve into a thoracic cavity of a living object and to deliver regular pacing during a post-operative period. The aortic valve may be deployed in a transcatheter aortic valve replacement/implantation (TAVR/TAVI) procedure without a need of an additional temporary or permanent pacemaker. The pacing device may be powered by wireless power transfer or by an embedded battery.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
57.
MULTIPLEXED WIRELESS SENSORS FOR PHYSIOLOGICAL MONITORING
An apparatus for non-invasively measuring physiological parameters of a mammal subject, comprising: a microcontroller unit adapted in wireless communication; at least one temperature sensing unit; and a pair of thermally conductive electrodes placed underneath the temperature sensing unit. The temperature sensing unit is thermally insulated to limit the temperature change by environmental effect from radiant heating, convection, and humidity to be within 0.5 °C. The pair of thermally conductive electrodes enables the thermal time constant less than 60 seconds. The microcontroller unit wirelessly transmits any sensor generated data and features to a base station.
Disclosed are methods for reprocessing thermoset polyurethane foams. The methods include mixing polyurethane foam particles loaded with a bond-exchange catalyst with a blowing agent and compounding the mixture. The methods comprise mechanically processing a polyurethane foam into particles; loading the particles with a bond-exchange catalyst, thereby preparing loaded particles; mixing the loaded particles with a blowing agent; compounding a mixture of the loaded particles and the blowing agent, thereby preparing a compounded substance; and extruding the compounded substance.
C08G 18/06 - Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
C08G 18/70 - Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
C08J 9/04 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent
C08J 9/12 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
59.
USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS IN ALZHEIMER'S DISEASE
Disclosed are neuronal nitric oxide synthase (nNOS) inhibitors for use in methods for reducing AβO-induced tau phosphorylation, reducing AβO formation and accumulation on neurons, and modulating neuronal nitric oxide synthase (nNOS).
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07C 39/205 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings
60.
WT-IDH1 INHIBITION USING A COVALENT AND BRAIN-PENETRANT SMALL MOLECULAR INHIBITOR FOR FERROPTOSIS INDUCTION IN HIGH-GRADE GLIOMA
Disclosed are methods of treating diseases or disorders associated with the expression of wild type isocitrate dehydrogenase 1 (IDH1). The disclosed methods may be utilized to treat diseases or disorders associated with cell proliferation, including cancer.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The United States of America as Represented by the Secretary, Department of Health and Human Service (USA)
Inventor
Wolin, Sandra
Boccitto, Marco
Cano, Juan Alberto Ortega
Kiskinis, Evangelos
Abstract
The present disclosure relates generally to compositions and methods for inhibiting dipeptide repeat protein (DPR)-ribosomal RNA (rRNA) interaction. In particular, the present technology relates to administering a therapeutically effective amount of one or more compositions that inhibit DPR-rRNA interaction to a subject diagnosed with, or at risk for DPR-associated pathologies, e.g., amyotrophic lateral sclerosis or frontotemporal dementia.
A system to predict heating in implants includes a memory configured to store one or more phase images of a medical implant that is implanted within a patient. The one or more phase images include the medical implant and tissue surrounding the medical implant. The one or more phase images are based on an imaging pre-scan of the patient. The system also includes a processor operatively coupled to the memory and configured to analyze the one or more phase images to determine values for one or more properties of the tissue surrounding the implant. The processor also predicts, based at least in part on the analyzed one or more phase images, a temperature increase of the medical implant that will occur during a subsequent imaging scan of the patient.
Endometrial cancer is classified and/or risk stratified using a suitably trained machine learning model. Risk classification of endometrial cancer is provided using a machine learning-based analysis of patient health data, such as clinicopathologic data, molecular data, and the like. Risk assessment is optimized for endometrial cancer, including risk of nodal involvement, distant metastasis, disease progression, and overall survival.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
64.
SELF-ASSEMBLING PEPTIDES WITH HYALURONIC ACID BINDING DOMAINS AND METHODS OF USE THEREOF
Provided herein are self-assembling peptides comprising hyaluronic acid binding domains, nanofibers and systems comprising the same, and methods of use thereof.
Provided herein are compositions and methods for the treatment of glioma by targeting TIM-3. In particular, a subject suffering from a glioma is administered a TIM-3 inhibitor alone or in combination with other glioma therapies.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
67.
SPHERICAL NUCLEIC ACIDS FOR cGAS-STING AND STAT3 PATHWAY MODULATION FOR THE IMMUNOTHERAPEUTIC TREATMENT OF CANCER
The disclosure is generally directed to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can activate a cytoplasmic DNA sensor including but not limited to cyclic GMP-AMP synthase (cGAS). In some embodiments, the SNAs also inactivate a transcription factor including but not limited to signal transducer and activator of transcription 3 (STATS). Methods of making and using the SNAs are also provided herein. In some aspects, the present disclosure provides a spherical nucleic acid (SNA) comprising (a) a nanoparticle core; and (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising a double-stranded or single-stranded stem loop DNA oligonucleotide that activates cyclic GMP-AMP synthase (cGAS) and is at least 15 base pairs in length.
The Board of Trustees of the Univ. of Illinois (USA)
Inventor
Appadurai, Vinesh
Narang, Akhil
Shah, Sanjiv J.
Slostad, Brody
Thomas, James David
Kansal, Mayank
Abstract
A system to distinguish subtypes of cardiac amyloidosis includes a memory configured to store an echocardiographic image of at least a portion of a heart. The system also includes a processor operatively coupled to the memory. The processor is configured to analyze the echocardiographic image to identify a region of interest of the heart. The processor also determines a septal reflectivity ratio of the region of interest. The processor also determines, based at least in part on the septal reflectivity ratio, a subtype of cardiac amyloidosis present in the region of interest.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
Methods for creating a conductive feature in a dielectric material are provided. In an embodiment, such a method comprises irradiating a region of a dielectric material having a resistivity of at least 108 Ω cm with a focused ion beam, the irradiated region corresponding to a conductive feature embedded in the dielectric material, the conductive feature having a conductivity greater than that of the dielectric material; and forming one or more contact pads of a conductive material in electrical communication with the conductive feature, the one or more contact pads configured to apply a voltage across the conductive feature using a voltage source.
Methods of forming unipolar radiation detectors having pixelated anodes are provided. The radiation detectors include a pixelated anode layer are made by segmenting a continuous metal film on a semiconductor substrate using laser ablation with a picosecond or femtosecond laser pulse. The semiconductor from which the substrate is formed includes at least three elements, at least one of which is an element selected from period five or period six of the Periodic Table of the Elements and another of which is selected from S, Se, Te, Cl, F, I and Br. The methods allow for the efficient fabrication of pixels with a high pattern precision.
The present invention provides engineered BRD4 polypeptides comprising deletions of one or more of bromodomain 1 (BD1), bromodomain 2 (BD2), and extra terminal domain (ET). Also provided are polynucleotides encoding the engineered BRD4 polypeptides, and constructs and vectors comprising the polynucleotides. Also provided are methods for using the engineered BRD4 polypeptides to assess the effects of candidate BRD4 C-terminal specific inhibitors on Pol II pausing.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
72.
CELL-FREE SYNTHESIS PLATFORM FOR ALLERGEN PRODUCTION
Disclosed are components, systems, and methods for synthesis of allergen proteins. The components, systems, and methods disclosed herein may be used in synthesizing allergen proteins in a cell-free protein synthesis (CFPS) system.
73.
MULTI-NODAL PHYSIOLOGICAL MONITORING SYSTEM UTILIZING MULTISPECTRAL PHOTOPLETHYSMOGRAPHY FOR ADVANCED HEMODYNAMIC CLASSIFICATION AND APPLICATIONS THEREOF
This invention relates to multi-nodal physiological monitoring systems and methods for measuring physiological parameters of a living subject, and applications of the same. Specifically, the system includes a central sensor to be disposed at a central position, such as a chest area, to measure electrocardiogram (ECG) and mechano-acoustic (MA) signals. At least one multi-spatial, multi-wavelength photoplethysmography (MWPPG) sensor is disposed at the central position or a peripheral position, such as a finger, of the living subject to acquire cardiac and vascular signals. The central sensor and the at least one MWPPG sensor may communicate and time-synchronize with each other wirelessly, and the ECG and MA signals from the central sensor and the cardiac and vascular signals from the at least one MWPPG sensor are processed to simultaneously extract hemodynamic metrics and local vascular metrics.
Disclosed herein is nanoparticulate monobenzone comprising a nanostructured carrier and monobenzone or a conjugate thereof embedded within the nanostructured carrier and methods of making and using the same. The nanostructured carrier can be a liposome o a metal-organic framework. Besides the monobenzone conjugate, the nanostructured carrier may further comprise a detectable label, a stabilizing agent, a targeting agent, linking agent, or any combination thereof and tailored for particular uses. The field of the invention relates to the use of nanoparticulate monobenzone in pharmaceutical compositions for treating melanoma.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Provided herein are engineered human spinal cord organoids and methods of use thereof for development and testing of therapeutic treatment for spinal cord injury.
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with subclinical acute rejection (subAR). These genes sets are useful for diagnosis, prognosis, monitoring of subAR.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
ANN AND ROBERT H. LURIE CHILDREN’S HOSPITAL OF CHICAGO (USA)
CLEARVOYA LLC (USA)
Inventor
Ansari, Sameer Ahmad
Cantrell, Donald Robinson
Cho, Leon
Zhou, Chaochao
Abstract
A system and method of differentiable X-ray projection (DiffXP) for generating digitally reconstructed radiographs (DRRs) and optimization of single-view X-ray pose estimations.
Multifunctional and regenerable N-chlorine based biocidal and detoxifying metal-organic frameworks are provided. Chloramine functional groups on the organic linkers of the metal-organic frameworks act as chlorine carriers. Pathogens or harmful organic compounds that come into contact with the metal-organic frameworks in the presence of water are rendered inactive by reactions with the active chlorine. The metal-organic frameworks can be incorporated into textiles used to make protective wearable articles.
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
A01N 55/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
A41D 13/11 - Protective face masks, e.g. for surgical use, or for use in foul atmospheres
Provided herein are compositions comprising a composite of peptide amphiphile nanofibers and hyaluronic acid (HA) particles, and methods of preparation and use thereof, such as for repair of a cartilage or osteochondral defects.
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
In certain aspects, a system-on-a-chip (SoC) for human activity recognition includes a plurality of integrated low-noise amplifiers configured to sense electromyogram (EMG) signals. The SoC includes a mixed-signal circuitry configured to receive the EMG signals from the plurality of integrated low-noise amplifiers, wherein the mixed-signal circuitry is configured to digitalize and extract time-domain features from the EMG signals. The SoC includes an artificial intelligence (AI) core comprising a reconfigurable neural network (NN) configured to receive, from the mixed-signal circuitry, the time-domain features that were extracted, wherein the reconfigurable NN is configured to recognize a local gesture based on time-domain features that is extracted. The SoC includes an analog data path circuitry configured to sense distance measurements and to transmit the distance measurements and the local gesture that is recognized.
In certain aspects, a compute-in-memory processor includes central computing units configured to operate in a central processing unit mode and a deep neural network mode. A data activation memory and a data cache output memory are in communication with the compute-in-memory processor. In the deep neural network mode, the data activation memory is configured as input memory and the data cache output memory is configured as output memory. In the central processing unit mode, the data activation memory is configured as a first data cache and the data cache output memory is configured as a register file and a second data cache.
G06F 7/501 - Half or full adders, i.e. basic adder cells for one denomination
G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using elements simulating biological cells, e.g. neuron
82.
Systems and Methods for Latent Variable Modeling of Multiscale Neural Signals for Brain-Computer Interfaces
Systems and methods for reconstructing spiking data from local field potential data are provided. In one implementation, the computer-implemented method may include receiving a training dataset of neural data for at least one subject. The training dataset may include measured field potential data and measured spiking data. In some examples, the method may further include training a neural network architecture to estimate spiking data from the field potential data. The neural network architecture may include a dynamics model.
An implantable, wireless cardiac hemodynamics monitor system includes a bio-sensing module and a wireless electronic subsystem. The bio-sensing module is implanted in a heart or an artery of the mammal subject to continuously monitor cardiac functions of the mammal subject. The wireless electronic subsystem is implanted between a fat layer and a dermis layer of a skin of the mammal subject and electrically connected to the bio-sensing module through insulated flexible wires. the wireless electronic subsystem is wirelessly communicated to an external wireless power transfer (WPT) module and an external user interface module. In operation, the wireless electronic subsystem is used to wirelessly receive power transferred from the external WPT module, and provide the power to the bio-sensing module; and to obtain sensing signals of the cardiac functions monitored by the bio-sensing module, and wirelessly transmit the sensing signals obtained to the external user interface module.
Provided is an aryl hydrocarbon receptor (AHR) agonist, wherein the AHR agonist negatively regulates T cell differentiation as well as methods of using such AHR agonist. Also provided herein are methods of use of transcription factors and gene knockout to negatively regulate T cell differentiation.
Disclosed herein are exosomes, compositions, and methods for the treatment of subjects infected with, or at risk for infection with a coronavirus, such as SARS-COV-2, HCoV-NL63, or SARS-COV. The disclosed exosomes comprise ACE2 protein and typically display ACE2 protein on the exosome surface. In some embodiment, the exosomes optionally are loaded with one or more additional therapeutic agents for treating an infection by a coronavirus, such as remdesivir. In some embodiments, compositions comprising the exosomes are administered to a subject in need thereof, e.g., to a subject diagnosed with, or suspected of having a SARS-COV-2 infection, an HCoV-NL63 infection, or a SARS-COV infection. In some embodiments, administration is via inhalation. In some embodiments, administration is via injection.
Disclosed are compositions and methods for treating amyotrophic lateral sclerosis (ALS) and compositions and methods for improving the health of diseased upper motor neurons. Particularly disclosed are compositions for improving the health of diseased upper motor neurons (UMNs) with additive effects in combination with drugs for treating ALS. The disclosed composition and methods may include or utilize (S)-5-(1-(3,5-bis(trifluoromethyl)phenoxy)ethyl)cyclohexane-1, 3-dione (NU-9), for example, in order to improve the health of diseased UMNs with additive effects in combination with drugs for treating ALS.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
87.
METHOD AND SYSTEM TO DECODE SPEECH PRODUCTION FROM NON-FRONTAL, NON-POST-CENTRAL BRAIN CORTICES
A system to decode communication signals includes a memory configured to store brain signals, where the brain signals originate from non-frontal, non-post-central cortices of a brain of a person. The system also includes a processor operatively coupled to the memory. The processor is configured to perform signal processing on the brain signals to identify one or more brain signal features. The processor is also configured to determine, based on the one or more identified brain signal features, whether the person intends to speak. Responsive to a determination that the person intends to speak, the processor identifies phonemes corresponding to the brain signals.
Polypyrrole polymers functionalized with thioanions and methods for their use in metal capture applications are provided. Also provided are methods for making the polypyrroles using anion exchange techniques. The thioanion-functionalized polypyrroles have a conjugated, positively charged backbone of pyrrole units that is charge-balanced with associated thioanions.
The disclosure is generally directed to immunostimulatory protein-core spherical nucleic acids (SNAs) comprising a protein core and a ratio of immunostimulatory and non-immunostimulatory strands, methods of making the immunostimulatory protein-core SNAs as well as their use.
One aspect of this invention relates to a method of forming a nanomaterial ink comprising providing an as-prepared (AP) semiconductor ink containing first nanosheets of at least one semiconductor; and megasonically exfoliating the AP semiconductor ink to form a megasonicated semiconductor ink containing second nanosheets of the at least one semiconductor.
A three-dimensional printing system is provided that includes a tank, a textured substrate connected to the tank, and an auxiliary reservoir. The tank contains a liquid photopolymer resin. The textured substrate is configured to allow light to pass through into the liquid photopolymer resin. The auxiliary reservoir contains lubricant, and the textured substrate includes a plurality of internal channels connected to the auxiliary reservoir.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
A three-dimensional printing system is provided that includes a tank, a textured substrate connected to the tank, and a reservoir. The tank contains a liquid photopolymer resin. The textured substrate is configured to allow light to pass through into the liquid photopolymer resin. The reservoir contains lubricant and is formed around a perimeter of the tank. The reservoir is connected to the textured substrate and configured to supply the lubricant to the textured substrate.
B29C 64/307 - Handling of material to be used in additive manufacturing
B29C 64/129 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (USA)
Inventor
Choi, Jaehyuk
Reinstein, Zachary Zale
Tsai, Kenneth
Abstract
Provided herein are novel compositions and methods using said compositions for treating Merkel cell carcinoma. More specifically, provided herein are compositions utilizing T cell receptors or combinations of cytokines, chemokines, and receptors that modulate the response of the immune system to detect and target cancer cells.
Disclosed herein are systems and methods for single-cell proteoform imaging mass spectrometry. The method includes moving a liquid droplet comprising a solvent across a substrate having disaggregated cells thereon, sampling the moving liquid droplet with an ionization source, wherein sampling the moving liquid droplet comprises detecting a discrete cell extraction profile comprising a multiplicity of proteoform ions when the moving liquid droplet contacts a disaggregated cell on the substrate, aggregating a mass-domain spectrum from a plurality of discreate cell extraction profiles; assigning a single cell proteoform from the aggregated mass-domain spectrum; and identifying one or more proteoforms from the assigned the single cell proteoform.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
96.
KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER
Provided herein are pharmaceutical compositions comprising KRAS inhibitors and HDAC inhibitors and methods of administering KRAS inhibitors and HDAC inhibitors for the treatment/prevention of cancer. In particular, an HDAC inhibitor is administered to overcome KRAS inhibitor resistance in KRAS, LKB1 mutant lung cancer.
Provided herein are synthetic scaffolds engineered to function as a pre-metastatic niche to detect metastasis. In particular, synthetic scaffolds described herein provide detection of the earliest events in metastasis, thereby enabling treatment of metastasis before the disease burden increases.
A ring sizer including a face plate that has markings usable to provide measurements of a valve. The sizer may include a clear face plate on which the markings are provided such that the valve is visible through the face plate facilitating accurate measurements of various valve dimensions and optimal ring sizing.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
99.
FUNCTIONAL FABRIC DEVICES HAVING INTEGRATED SENSORS
Provided herein are smart functional fabrics and therapeutic/diagnostic garments which utilize flexible wireless electronic devices to enhance functionality, for example, by measuring key therapy parameters and providing data to clinicians, and methods utilizing such devices. The provided methods are designed to avoid patient discomfort and decrease harm or irritation caused by garments which utilize bulkier, more rigid sensors. Additionally, the described devices are multiplexed to allow for sensing of multiple parameters of therapeutic interest and combinations of measured data for new clinical metrics.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
NORTHWESTERN UNIVERSITY (USA)
Inventor
Willomitzer, Florian
Cornwall, Patrick
Ballester, Manuel
Wang, Heming
Abstract
Methods, devices and systems for generating shaped, synthetic light patterns based on measured optical signals are described that are subsequently processed to generate the desired synthetic fields. By combining synthetic fields with particular amplitude, phase and/or spectral values, a desired synthetic light illumination pattern can be conceived based on the measured optical signals. The synthetic fields can then be computationally propagated in time and space to understand the characteristics of the propagated light and/or characteristics of the intervening objects.
G01S 17/34 - Systems determining position data of a target for measuring distance only using transmission of continuous waves, whether amplitude-, frequency-, or phase-modulated, or unmodulated using transmission of continuous, frequency-modulated waves while heterodyning the received signal, or a signal derived therefrom, with a locally-generated signal related to the contemporaneously transmitted signal
G01S 17/88 - Lidar systems, specially adapted for specific applications
G01S 17/10 - Systems determining position data of a target for measuring distance only using transmission of interrupted, pulse-modulated waves
G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
